-DOCSTART- -X- O
Viral -X- _ B-Patient
hepatitis -X- _ I-Patient
, -X- _ O
as -X- _ O
an -X- _ O
international -X- _ O
public -X- _ O
health -X- _ O
concern -X- _ O
, -X- _ O
seriously -X- _ O
affects -X- _ O
communities -X- _ O
and -X- _ O
health -X- _ O
system. -X- _ O
In -X- _ O
recent -X- _ O
years -X- _ O
, -X- _ O
great -X- _ O
strides -X- _ O
have -X- _ O
been -X- _ O
taken -X- _ O
for -X- _ O
development -X- _ O
of -X- _ O
new -X- _ O
potential -X- _ O
tools -X- _ O
against -X- _ O
viral -X- _ B-Patient
hepatitis. -X- _ I-Patient
Among -X- _ O
these -X- _ O
efforts -X- _ O
, -X- _ O
a -X- _ O
valuable -X- _ O
strategy -X- _ O
introduced -X- _ O
new -X- _ O
molecules -X- _ O
called -X- _ O
“aptamers”. -X- _ B-Intervention
Aptamers -X- _ B-Intervention
as -X- _ O
potential -X- _ O
alternatives -X- _ O
for -X- _ O
antibodies -X- _ O
could -X- _ O
be -X- _ O
directed -X- _ O
against -X- _ O
any -X- _ O
protein -X- _ O
in -X- _ O
infected -X- _ O
cells -X- _ O
and -X- _ O
any -X- _ O
components -X- _ O
of -X- _ O
viral -X- _ O
particles. -X- _ O
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
will -X- _ O
focus -X- _ O
on -X- _ O
recent -X- _ O
advances -X- _ O
in -X- _ O
the -X- _ O
diagnosis -X- _ O
and -X- _ O
treatment -X- _ O
of -X- _ O
viral -X- _ B-Patient
hepatitis -X- _ I-Patient
based -X- _ O
on -X- _ O
aptamer -X- _ B-Intervention
technology. -X- _ I-Intervention
In -X- _ O
recent -X- _ O
years -X- _ O
, -X- _ O
various -X- _ O
types -X- _ O
of -X- _ O
aptamers -X- _ B-Intervention
including -X- _ I-Intervention
RNA -X- _ I-Intervention
and -X- _ I-Intervention
DNA -X- _ I-Intervention
were -X- _ O
introduced -X- _ O
against -X- _ O
viral -X- _ B-Patient
hepatitis. -X- _ I-Patient
Some -X- _ B-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
aptamers -X- _ I-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
utilized -X- _ I-Outcome
for -X- _ I-Outcome
early -X- _ I-Outcome
and -X- _ I-Outcome
precise -X- _ I-Outcome
diagnosis -X- _ I-Outcome
of -X- _ I-Outcome
hepatitis -X- _ I-Outcome
infections -X- _ I-Outcome
and -X- _ I-Outcome
other -X- _ I-Outcome
group -X- _ I-Outcome
selected -X- _ I-Outcome
as -X- _ I-Outcome
therapeutic -X- _ I-Outcome
tools -X- _ I-Outcome
against -X- _ I-Outcome
viral -X- _ I-Outcome
targets. -X- _ I-Outcome
Designing -X- _ O
diagnostic -X- _ O
and -X- _ O
therapeutic -X- _ O
platforms -X- _ O
based -X- _ O
on -X- _ O
aptamer -X- _ B-Intervention
technology -X- _ I-Intervention
is -X- _ O
a -X- _ O
promising -X- _ O
approach -X- _ O
in -X- _ O
viral -X- _ O
infections. -X- _ O
The -X- _ O
obtained -X- _ O
aptamers -X- _ O
in -X- _ O
the -X- _ O
recent -X- _ O
years -X- _ O
showed -X- _ O
obvious -X- _ B-Outcome
potential -X- _ I-Outcome
for -X- _ I-Outcome
use -X- _ I-Outcome
as -X- _ I-Outcome
diagnostic -X- _ I-Outcome
and -X- _ I-Outcome
therapeutic -X- _ I-Outcome
tools -X- _ I-Outcome
against -X- _ I-Outcome
viral -X- _ I-Outcome
hepatitis. -X- _ I-Outcome
Although -X- _ O
some -X- _ O
modifications -X- _ O
to -X- _ O
increase -X- _ O
the -X- _ O
biostability -X- _ O
and -X- _ O
half-life -X- _ O
of -X- _ O
aptamers -X- _ O
are -X- _ O
underway -X- _ O
, -X- _ O
it -X- _ O
seems -X- _ O
these -X- _ O
molecules -X- _ O
will -X- _ O
be -X- _ O
a -X- _ O
favorable -X- _ O
substitute -X- _ O
for -X- _ O
monoclonal -X- _ O
antibody -X- _ O
in -X- _ O
near -X- _ O
future -X- _ O
. -X- _ O

